

BCC

**Biotechnology
Commercialization
Center**



The Biotechnology Commercialization Center (BCC), located in the University Center Tower at UTHealth, is available for incubation of start-up companies. The BCC's mission is to help commercialize and incubate UTHealth and Houston-based technologies, while increasing the number of Texas-based companies. Located within the heart of the Texas Medical Center, the BCC provides valuable access to information, collaboration and expertise.

BIOHOUSTON
BUILDING THE LIFE SCIENCE FUTURE

In partnership with: TEXAS BIOALLIANCE

ati austin technology
incubator

Key features of the BCC

- ~15,000 sq. ft of laboratory, office, and shared areas on 3 floors dedicated to start-up companies
- Access to UTHealth core laboratory and animal services as well as capital equipment
- Conference and meeting spaces
- Shared building services
- Onsite Parking

About the Office of Technology Management

The Office of Technology Management (OTM) is led by Bruce D. Butler, Ph.D., Vice President for Research and Technology and has four additional licensing managers, one patent manager and two support staff. OTM manages over 150 active license/option agreements, with over 90 currently generating income, and over 1,000 U.S. and foreign patents/patent applications. Thirty-five UTHealth Portfolio Companies have been created to date. Total cumulative gross revenues received by UTHealth for commercialized technologies exceeds \$52 million. OTM executes over 25 new license/option agreements per year. For more information, including technologies available for license, please contact OTM.

About UTHealth

- UTHealth is comprised of the Medical School, the Dental Branch, the Graduate School of Biomedical Sciences, the School of Public Health, the School of Nursing, the School of Health Information Sciences, the Brown Foundation Institute of Molecular Medicine, the UT Harris County Psychiatric Center, and the Children's Learning Institute.
- UTHealth has nearly 100 clinical training sites, and has research expenditures totaling more than \$221 million, with over 900 research projects in progress.

OTM Startup Contacts

Bruce D. Butler, Ph.D.

Vice President for Research and Technology
(713) 500-3369

Bruce.D.Butler@uth.tmc.edu

Christine E. Flynn, Ph.D.

Assistant Director for New Venture Development
(713) 500-3383 direct

Christine.Flynn@uth.tmc.edu

For more information on Start-ups, the BCC, the EIR Program and more, please visit OTM's website:

www.uth.edu/otm

Start-up Companies from UTHealth



UTHealth
The University of Texas
Health Science Center at Houston

Office of Technology Management
7000 Fannin, Suite 720
Houston, TX 77030
(713) 500-3369
otm@uth.tmc.edu
www.uth.edu/otm

UTHealth Start-up Activity

Thirty-five portfolio start-up companies have licensed UTHealth technologies, and currently have over 19 products on the market. UTHealth portfolio companies have raised more than \$173 million in funding. Four companies are recipients of Texas Emerging Technology Fund grants, totaling \$9.5 million, and three received UT System Horizon Fund investments. Two UTHealth portfolio companies have had an IPO or have been acquired with a combined market cap of greater than \$2.9B: Volcano (VOLC-NASDC) and LifeCell (acquired by KCI).

UTHealth portfolio companies have created more than 80 jobs in private companies, and more than 1400 in 2 publicly traded companies.

Recent UTHealth Start-up Achievements

Cerevast Therapeutics, Inc. received CE mark clearance in Europe for its Clotbust ER™ device for ultrasound treatment of ischemic stroke. Cerevast is currently conducting a worldwide Phase 3 clinical study.



PLx Pharma Inc. received NDA approval for sale from the FDA for its GI-safe PL2200 aspirin product for treatment of pain and fever and for cardio prevention.



EMIT Corporation's HypothermX™ HX100, a portable intravenous fluid warmer, was approved by the FDA for treatment of hypothermia and has been deployed by Special Forces in Afghanistan.



Start-up Funding Opportunities

State of Texas, Federal & UTHealth Funding Sources

The Texas Emerging Technology Fund (ETF) was created by the State of Texas Legislature to provide funding coupled with additional federal and private investments for Texas-based companies.

The Cancer Prevention and Research Institute of Texas (CPRIT) was established by the State of Texas Legislature to provide \$3 billion in funding for innovation in cancer research, including projects with potential for commercialization. Current opportunities include relocation, established company product development and new company product development awards.

The University of Texas System Horizon Fund (UTHF) is the strategic venture fund of the University of Texas System. Its dual mission is to improve commercialization of technologies out of research at UT System institutions, including UTHealth, and to provide a positive return on investment.

The New Venture Development Fund was established to create and assist startup companies in the development and commercialization of UTHealth technologies, through market analysis, business plan development, regulatory planning, corporate document preparation, and in some cases, providing initial seed capital for innovative technologies.

The Small Business Innovation Research (SBIR) Program and the **Small Business Technology Transfer (STTR) Program** are sponsored by the U.S. Small Business Administration (SBA) to promote the development of small, high-tech, innovative businesses in the United States.

Find out more:
www.uth.edu/otm/funding-opportunities/

Entrepreneur-in-Residence Program

OTM established an Entrepreneur-in-Residence (EIR) Program, co-funded by an ETF Incentive Award, to facilitate new venture activity for UTHealth technologies. EIR participants are often serial entrepreneurs looking for the next "latest and greatest" technology to spin into a new commercial entity.

EIR participants at UTHealth typically are involved in the analysis of UTHealth technologies, including benchmarking, assessments, clinical validation, platform alternatives, and competitive market analyses. EIRs formalize such analyses into business plans, including initial key milestones and financials. In some instances, EIRs may take the lead on company formation around a particular technology as CEO.

Regulatory Affairs EIRs may be engaged to develop early stage plans for FDA submission, preclinical studies and clinical trial staging.

FAQs About Start-ups at UTHealth

- **Can UTHealth faculty participate in the formation of & hold positions in a new start-up?** Yes, with departmental chair approval and applicable conflict of interest management plan, although OTM encourages participation be limited to Scientific Advisory Board (SAB).
- **If my invention is licensed to a company, what compensation will I receive?** Compensation may include equity in the company, a share in licensing or royalty revenues received by UTHealth, sponsored research funding, or income if you are a consultant of the company or a member of the SAB.
- **If my invention is licensed to a UTHealth start-up company, can I perform sponsored research for the company?** Yes, you may perform sponsored research under an approved sponsored research agreement. A conflict of interest management plan must also be established to be certain that the research follows University and UT System guidelines.